Cargando…
ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern
COVID-19, an infectious disease caused by the SARS-CoV-2 virus, emerged globally in early 2020 and has remained a serious public health issue. To date, although several preventative vaccines have been approved by FDA and EMA, vaccinated individuals increasingly suffer from breakthrough infections. T...
Autores principales: | Tsai, Tsung-I, Khalili, Jahan S., Gilchrist, Mark, Waight, Andrew B., Cohen, Daniella, Zhuo, Shi, Zhang, Yong, Ding, Muran, Zhu, Hai, Mak, Amanda Nga-Sze, Zhu, Yi, Goulet, Dennis R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882475/ https://www.ncbi.nlm.nih.gov/pubmed/35240221 http://dx.doi.org/10.1016/j.antiviral.2022.105271 |
Ejemplares similares
-
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2022) -
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2023) -
Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
por: Goulet, Dennis R., et al.
Publicado: (2022) -
Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
por: Higuchi, Yusuke, et al.
Publicado: (2021) -
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
por: Khalili, Jahan S., et al.
Publicado: (2020)